Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611–22.

Article  PubMed  PubMed Central  Google Scholar 

Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, et al. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS ONE. 2017;12(10): e0186549.

Article  PubMed  PubMed Central  Google Scholar 

Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–8.

Article  CAS  PubMed  Google Scholar 

Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, Study HACM. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99(12):962–72.

Article  Google Scholar 

Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, et al. Hodgkin lymphoma in the Swiss HIV cohort study. Blood. 2009;113(23):5737–42.

Article  CAS  PubMed  Google Scholar 

Vaughan J, Perner Y, McAlpine E, Wiggill T. Brief report: HIV-associated Hodgkin lymphoma involving the bone marrow identifies a very high-risk subpopulation in the era of widescale antiretroviral therapy use in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020;83(4):345–9.

Article  PubMed  Google Scholar 

Patel M, Philip V, Fazel F. Human immunodeficiency virus infection and Hodgkin’s lymphoma in South Africa: an emerging problem. Adv Hematol. 2011;2011: 578163.

Article  PubMed  PubMed Central  Google Scholar 

Swart L, Novitzky N, Mohamed Z, Opie J. Hodgkin lymphoma at Groote Schuur hospital, South Africa: the effect of HIV and bone marrow infiltration. Ann Hematol. 2019;98(2):381–9.

Article  CAS  PubMed  Google Scholar 

Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, et al. High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART Era, ANRS CO16 LYMPHOVIR cohort. Clin Infect Dis. 2015;61(9):1469–75.

Article  CAS  PubMed  Google Scholar 

Xicoy B, Miralles P, Morgades M, Rubio R, Valencia ME, Ribera JM. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin’s lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. Haematologica. 2013;98(8):e85–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23(2):274–81.

McGee-Avila JK, Suneja G, Engels EA, Rositch AF, Horner MJ, Luo Q, et al. Cancer treatment disparities in people with HIV in the United States, 2001–2019. J Clin Oncol. 2024;42(15):1810–20.

Article  PubMed  Google Scholar 

Moahi K, Ralefala T, Nkele I, Triedman S, Sohani A, Musimar Z, et al. HIV and Hodgkin lymphoma survival: a prospective study in Botswana. JCO Glob Oncol. 2022;8: e2100163.

Article  PubMed  PubMed Central  Google Scholar 

Mponda M, Kudowa E, Craven DM, Eastburg LC, Chikasema M, Kasonkanji E, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. EClinicalMedicine. 2024;69: 102480.

Article  PubMed  PubMed Central  Google Scholar 

O’Malley DP, Dogan A, Fedoriw Y, Medeiros LJ, Ok CY, Salama ME. American Registry of Pathology Expert Opinions: immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol. 2019;39:105–10.

Article  PubMed  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.

Article  PubMed  PubMed Central  Google Scholar 

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506–14.

Fry KFR, Chakraborty NM. Measuring equity with nationally representative wealth quintiles. 2014 [Available from: https://media.psi.org/wp-content/uploads/2020/02/31012157/Wealth-Quintile-Guide.pdf.

Rutstein SO. Steps to constructing the new DHS Wealth Index. Rockville, MD: ICF International. 2015;6.

Kaplan EM, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.

Article  Google Scholar 

Brookmeyer RC, J.J. A confidence interval for the median survival time. Biometrics. 1982;38:29.

Rubio R. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative study group of malignancies associated with HIV infection of Madrid. Cancer. 1994;73(9):2400–7.

Masel R, Roche ME, Martinez-Outschoorn U. Hodgkin lymphoma: a disease shaped by the tumor micro- and macroenvironment. Best Pract Res Clin Haematol. 2023;36(4): 101514.

Article  CAS  PubMed  Google Scholar 

Dasaradhan T, Koneti J, Kalluru R, Gadde S, Cherukuri SP, Chikatimalla R. Tuberculosis-associated anemia: a narrative review. Cureus. 2022;14(8): e27746.

PubMed  PubMed Central  Google Scholar 

Vellemans H, Andre MPE. Review of treatment options for the management of advanced stage Hodgkin lymphoma. Cancers. 2021;13(15).

Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016;30(5):787–96.

Article  CAS  PubMed  Google Scholar 

Grewal R, Irimie A, Naidoo N, Mohamed N, Petrushev B, Chetty M, et al. Hodgkin’s lymphoma and its association with EBV and HIV infection. Crit Rev Clin Lab Sci. 2018;55(2):102–14.

Article  PubMed  Google Scholar 

Lupo J, Truffot A, Andreani J, Habib M, Epaulard O, Morand P, et al. Virological Markers in Epstein-Barr Virus-Associated Diseases. Viruses. 2023;15(3).

Shamay M, Kanakry JA, Low JSW, Horowitz NA, Journo G, Ahuja A, et al. CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. Blood Adv. 2020;4(8):1624–7.

Article  PubMed  PubMed Central  Google Scholar 

Mbai MM, Mduma E, Thuo S, Rugengamanzi E, Malichewe CV, Lugina EL. A comparison of clinical profile and treatment outcome of Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era. BMC Cancer. 2024;24(1):796.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023;10(8):e624–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrera AF, LeBlanc ML, Castellino SM, Li H, Rutherford SC, Evens AM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). Journal of Clinical Oncology. 2023;41(17_suppl):LBA4-LBA.

Graeter A, Bowles KE, Coghill A. Safety and efficacy of immune checkpoint inhibitors in the treatment of hodgkin lymphoma in people living with human immunodeficiency virus: a case series. Blood. 2023;142:6176.

Article  Google Scholar 

Vogt SL, Maloma L, Xian RR, Ambinder RF, Philip V, Patel M, et al. Significance of lymph node fine needle aspiration for the diagnosis of HIV-associated lymphoma in a low-resource setting. AIDS. 2022;36(10):1393–8.

CAS  PubMed  Google Scholar 

Gopal S. The case for prioritizing malignant hematology services in low- and middle-income countries. Semin Hematol. 2023;60(4):189–91.

Article  PubMed  PubMed Central  Google Scholar